Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and s...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
NeOnc_Technologies
NeOnc_Technologies Feb. 3 at 10:30 AM
$NTHI Amir Heshmatpour Discusses Launch of NeOnc Technologies’ Clinical Trials in Israel: “We submitted all the documents for the start of experiments with Prof. Dvora Blumenthal at Ichilov Hospital. She also knows Dr. Chen - it’s a small world in these areas. I believe we'll start in two months.”
0 · Reply
FranciscaAlverez
FranciscaAlverez Feb. 3 at 1:28 AM
$NTHI Interesting to see more attention on NeOnc’s approach to brain cancer. Repurposing existing drugs to slow aggressive tumors could be a smarter, faster path than starting from scratch. Still early, but this is the kind of research worth watching closely.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Feb. 2 at 1:47 PM
$NTHI We’d like to congratulate USC Spine Center Surgeons, including NeOnc Technologies own Dr. Thomas Chen, who have been named to the Castle Connolly 2026 Top Doctors list: • Thomas Chen, MD • Patrick Hsieh, MD • John Liu, MD • Jeffrey Wang, MD Castle Connolly Top Doctors represent approximately the top 7% of practicing physicians in the United States and are selected through a peer-nomination process and independent physician-led research. NeOnc congratulates these physicians for their continued commitment to clinical excellence and patient care. #NeOncTechnologies #USC #SpineCenter #CastleConnolly #TopDoctors #HealthcareLeadership #ClinicalExcellence
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 30 at 2:01 PM
$NTHI NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 29 at 10:55 PM
$NTHI Current Stock Price: $8.70
0 · Reply
peepthestamp
peepthestamp Jan. 29 at 2:01 PM
$NTHI - Buy Lows
0 · Reply
topstockalerts
topstockalerts Jan. 28 at 7:04 PM
$NTHI It just took off with strong follow-through 🚀. Buyers didn’t hesitate. Momentum is fully engaged.
0 · Reply
GioBona
GioBona Jan. 27 at 11:42 PM
$NTHI Neuro-oncology is one of the hardest areas in cancer. NTHI focusing on targeted brain tumor treatments is exactly where innovation is needed. High risk, but real unmet need.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 26 at 12:02 PM
$NTHI NeOnc Technologies Featured in Globes (Israel) NeOnc Technologies was recently featured in Globes, highlighting the Company’s expansion into Israel and the Middle East as it advances clinical development of its brain cancer programs. Key highlights: •⁠ ⁠Clinical trials in Israel - Preparations underway to initiate trials leveraging Israel’s advanced biotech and clinical infrastructure •⁠ ⁠Novel CNS delivery approach - Intranasal platform designed to bypass the blood–brain barrier •⁠ ⁠Advancing clinical pipeline - Ongoing efficacy studies following encouraging Phase I safety data •⁠ ⁠Expanded regional presence - Strategic investment supports continued trials and geographic expansion NeOnc remains focused on disciplined clinical execution and long-term shareholder value. https://en.globes.co.il/en/article-the-iranian-businessman-testing-a-cancer-drug-in-israel-1001532408
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 21 at 10:47 AM
$NTHI We see the recent preclinical findings on NEO100 combined with focused ultrasound as a significant step forward in the development of brain-penetrant therapies for CNS cancers. Brain tumors remain among the most challenging cancers to treat, largely due to the blood–brain barrier, which limits drug delivery and the effectiveness of conventional therapies. These results highlight several exciting advances: 1. Enhanced Potency Through Synergy 2. AI-Guided Precision 3. Rapid, Patient-Relevant Modeling 4. Broad Applicability These findings reinforce NEO100’s potential as a first-in-class, noninvasive sonodynamic therapy, representing a meaningful opportunity to advance treatment options for patients with historically limited choices. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-nasdaq-nthi-announces-ai-driven-findings
0 · Reply
Latest News on NTHI
NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Jan 30, 2026, 9:00 AM EST - 4 days ago

NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

Jan 9, 2026, 7:32 PM EST - 25 days ago

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)

NeOnc Technologies Reports Updated Clinical Results

Dec 15, 2025, 9:00 AM EST - 7 weeks ago

NeOnc Technologies Reports Updated Clinical Results

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

Dec 1, 2025, 9:00 AM EST - 2 months ago

NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

Nov 13, 2025, 9:00 AM EST - 2 months ago

NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

Nov 7, 2025, 9:00 AM EST - 3 months ago

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

NeOnc Technologies: From Survival Mode To Expansion Mode

Oct 9, 2025, 2:25 PM EDT - 4 months ago

NeOnc Technologies: From Survival Mode To Expansion Mode

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 5 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 6 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 6 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 7 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 8 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 10 months ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 10 months ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 10 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 10 months ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 11 months ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 11 months ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 11 months ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 11 months ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 1 year ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 2 years ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 2 years ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

NeOnc_Technologies
NeOnc_Technologies Feb. 3 at 10:30 AM
$NTHI Amir Heshmatpour Discusses Launch of NeOnc Technologies’ Clinical Trials in Israel: “We submitted all the documents for the start of experiments with Prof. Dvora Blumenthal at Ichilov Hospital. She also knows Dr. Chen - it’s a small world in these areas. I believe we'll start in two months.”
0 · Reply
FranciscaAlverez
FranciscaAlverez Feb. 3 at 1:28 AM
$NTHI Interesting to see more attention on NeOnc’s approach to brain cancer. Repurposing existing drugs to slow aggressive tumors could be a smarter, faster path than starting from scratch. Still early, but this is the kind of research worth watching closely.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Feb. 2 at 1:47 PM
$NTHI We’d like to congratulate USC Spine Center Surgeons, including NeOnc Technologies own Dr. Thomas Chen, who have been named to the Castle Connolly 2026 Top Doctors list: • Thomas Chen, MD • Patrick Hsieh, MD • John Liu, MD • Jeffrey Wang, MD Castle Connolly Top Doctors represent approximately the top 7% of practicing physicians in the United States and are selected through a peer-nomination process and independent physician-led research. NeOnc congratulates these physicians for their continued commitment to clinical excellence and patient care. #NeOncTechnologies #USC #SpineCenter #CastleConnolly #TopDoctors #HealthcareLeadership #ClinicalExcellence
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 30 at 2:01 PM
$NTHI NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 29 at 10:55 PM
$NTHI Current Stock Price: $8.70
0 · Reply
peepthestamp
peepthestamp Jan. 29 at 2:01 PM
$NTHI - Buy Lows
0 · Reply
topstockalerts
topstockalerts Jan. 28 at 7:04 PM
$NTHI It just took off with strong follow-through 🚀. Buyers didn’t hesitate. Momentum is fully engaged.
0 · Reply
GioBona
GioBona Jan. 27 at 11:42 PM
$NTHI Neuro-oncology is one of the hardest areas in cancer. NTHI focusing on targeted brain tumor treatments is exactly where innovation is needed. High risk, but real unmet need.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 26 at 12:02 PM
$NTHI NeOnc Technologies Featured in Globes (Israel) NeOnc Technologies was recently featured in Globes, highlighting the Company’s expansion into Israel and the Middle East as it advances clinical development of its brain cancer programs. Key highlights: •⁠ ⁠Clinical trials in Israel - Preparations underway to initiate trials leveraging Israel’s advanced biotech and clinical infrastructure •⁠ ⁠Novel CNS delivery approach - Intranasal platform designed to bypass the blood–brain barrier •⁠ ⁠Advancing clinical pipeline - Ongoing efficacy studies following encouraging Phase I safety data •⁠ ⁠Expanded regional presence - Strategic investment supports continued trials and geographic expansion NeOnc remains focused on disciplined clinical execution and long-term shareholder value. https://en.globes.co.il/en/article-the-iranian-businessman-testing-a-cancer-drug-in-israel-1001532408
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 21 at 10:47 AM
$NTHI We see the recent preclinical findings on NEO100 combined with focused ultrasound as a significant step forward in the development of brain-penetrant therapies for CNS cancers. Brain tumors remain among the most challenging cancers to treat, largely due to the blood–brain barrier, which limits drug delivery and the effectiveness of conventional therapies. These results highlight several exciting advances: 1. Enhanced Potency Through Synergy 2. AI-Guided Precision 3. Rapid, Patient-Relevant Modeling 4. Broad Applicability These findings reinforce NEO100’s potential as a first-in-class, noninvasive sonodynamic therapy, representing a meaningful opportunity to advance treatment options for patients with historically limited choices. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-nasdaq-nthi-announces-ai-driven-findings
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 20 at 10:51 AM
$NTHI When we look at recurrent Grade III/IV IDH1-mutant astrocytoma, treatment options have historically been extremely limited. Salvage therapies rarely produce meaningful tumor responses, typically under 8% radiographic remission, and long-term survival beyond a year is uncommon. That’s why the intranasal NEO100 results are so compelling: Radiographic remission in 24% of patients, three times higher than historical expectations. 44% achieved six-month progression-free survival, exceeding benchmarks for this population. Durable survival: more than a third of patients are alive ≥18 months post-treatment. Well-tolerated: even with chronic administration, no significant toxicity observed. What makes NEO100 truly exciting is that it’s first-in-class, CNS-penetrant, and metabolically active, meaning it can reach the brain directly and sustain tumor response. https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-reports-updated-clinical-results-0
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 19 at 12:19 PM
$NTHI Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) Key Takeaways: • Positive Phase 1/2a results for NEO100 announced in December • NEO100 Phase 2a top-line read out expected in Mid-2026 • Closing and funding of the Quazar Investment expected in the near-term https://www.nasdaq.com/press-release/stonegate-capital-partners-initiates-coverage-neonc-technologies-holdings-inc-nthi
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 13 at 1:15 PM
$NTHI 2025 was a transformative year for NeOnc Technologies. Across clinical execution, leadership expansion, capital formation, IP strength, and strategic growth, NeOnc Technologies made meaningful progress advancing its mission to address some of the most challenging brain cancers. 2025 Highlights Include: - Clinical & Regulatory Progress - Leadership & Scientific Advisory Expansion - Strategic Transactions & Capital Formation - Technology, IP & Innovation - Visibility, Recognition & Funding With a strengthened foundation, advancing clinical programs, and an expanded leadership and technology platform, NeOnc enters 2026 positioned for continued clinical milestones and strategic growth. We look forward to an even more impactful year ahead.
0 · Reply
MistyMichelle
MistyMichelle Jan. 10 at 9:21 PM
$NTHI There was news today on a partnership today does anyone know anything about it I think?
0 · Reply
newsfile_corp
newsfile_corp Jan. 10 at 12:33 AM
https://nfne.ws/279982 $NTHI @reportablenews #NASDAQ #Investing
0 · Reply
SabiMesh0928
SabiMesh0928 Jan. 6 at 6:38 AM
Stocks like $NTHI, $ONCY and $CRSP have moved off their lows which makes me curious whether this is just stock specific noise or the start of broader interest returning to the space. Interested to hear what y'all think about this?
1 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 5 at 12:02 PM
$NTHI We are proud to share this short video highlighting pediatric DIPG patients in China participating in investigator-sponsored studies evaluating NEO100-03, an investigational intranasal therapy developed by NeOnc Technologies Holdings Inc NTHI. These children were diagnosed with diffuse intrinsic pontine glioma (DIPG)—a rare and aggressive pediatric brain cancer with limited treatment options. Patients received NEO100-03 following prior standard therapies, including radiotherapy, and continue treatment under clinical supervision. These stories highlight the urgent unmet medical need in pediatric brain cancer and reinforce the importance of continued clinical research into novel, non-invasive therapeutic approaches. https://www.linkedin.com/posts/neonctechnologiesholdingsinc_neonc-pediatriccancer-braincancerresearch-activity-7412989512936501248-Jmty?utm_source=share&utm_medium=member_desktop&rcm=ACoAAC68kW4BF0blKTQDwJw2sDLQ-wHyj4tKckg
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Jan. 4 at 4:21 AM
$NTHI As we celebrate the New Year, NeOnc Technologies extends our sincere thanks to patients, clinicians, partners, and shareholders for your continued trust and support. We look forward to advancing our mission in 2026 and driving meaningful progress for patients in need. Wishing everyone a healthy and successful New Year.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 25 at 11:54 AM
$NTHI “The consistency and durability of these responses continue to exceed expectations. With radiographic responses now 300% higher than historically reported salvage therapies, these data reinforce our conviction that NEO100 may represent a meaningful advance for patients with recurrent IDH1-mutant gliomas.” - Amir F. Heshmatpour, Executive Chairman, President & CEO, NeOnc Technologies Independent experts have described the results as a potential paradigm shift in this hard-to-treat disease. #NeOnc #NTHI #BiotechNews #CNS #CancerResearch #LongTermSurvival #IR
0 · Reply
InductionInv
InductionInv Dec. 25 at 9:42 AM
$NTHI Forward momentum is increasingly dictated by operational clarity, because growth without leverage now attracts skepticism. Clear follow‑through could unlock sustainable re‑rating.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Dec. 24 at 11:36 AM
$NTHI Our recent news on intranasal NEO100 is highly encouraging - updated results from NeOnc’s Phase 1/2a and compassionate-use experience show: • 24% radiographic remission (6/25 patients) • 44% PFS-6, vs. 21–31% historical benchmarks • 36% alive ≥18 months post-treatment • No significant toxicity with chronic dosing These outcomes exceed typical salvage therapy results and reinforce the durability and reproducibility of NEO100’s clinical signal. #NTHI #BiotechStocks #ClinicalData #BrainTumor #IDH1 #Investing #Healthcare
0 · Reply
BlueSkyBuyer
BlueSkyBuyer Dec. 24 at 10:19 AM
$NTHI Market attention is shifting toward whether execution velocity aligns with stated operational milestones. Execution slippage remains the dominant downside risk.
0 · Reply